Medical Developments International Limited
0.27
USD
-0.05
(-14.22%)
ISIN
AU000000MVP2
Return %
Stock
S&P 500
1Y
-15.08
14.20
3Y
-47.06
81.12
5Y
-94.32
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Anita James
- Full Time Employees
- 68
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 4 Caribbean Drive Scoresby VIC Australia 3179
- IPO Date
- Nov 24, 2003
- Website
- medicaldev.com
- Similar Companies
- Business
- Medical Developments International Limited (ASX:MVP) manufactures and distributes specialised healthcare products focused on acute pain management and respiratory care. The company offers Penthrox, a non-opioid inhaled analgesic for trauma, emergency, and procedural pain relief delivered via a green whistle device; a range of respiratory devices including spacers and nebulisers such as the Breath-A-Tech brand to manage asthma and chronic obstructive pulmonary disease (COPD); and veterinary equipment for animal care. These products serve hospitals, ambulance services, sports medicine, general practitioners, and veterinary professionals. Founded in 1971 and headquartered in Scoresby, Victoria, Australia, Medical Developments International Limited operates globally with products registered in over 28 countries across Australia, Asia, Europe, and the United States. The company maintains state-of-the-art manufacturing facilities in Scoresby and emphasises innovation through partnerships like those with Australia's CSIRO. Recent developments include a strategic partnership with Labatec Pharma SA to enhance Penthrox commercialisation and market access in Switzerland, supporting a transition to a partner-supported operating model; signals at the 2025 AGM of accelerated volume growth for Penthrox through deeper partner engagement, publication of MAGPIE paediatric trial data, new health-economic analyses, and increased investment in commercial and medical affairs particularly in Australia; ongoing US respiratory market expansion; and a director's market acquisition of 62,858 ordinary shares in September 2025 reflecting internal confidence. Revenue reached $33.2 million in FY24, with FY25 sales at $39.1 million and a return to positive net profit.
Company News
Medical Developments International Limited (MDDVF) Discusses Leadership Transition, Business Performance, and Strategic Growth Initiatives Transcript
Medical Developments International Limited (MDDVF) Q4 2026 Earnings Call Transcript